Moreover, our group have reported that BCMA or CD19 CAR-T cells expressing IL-7 and CCL19 may represent a promising therapy for relapsed/refractory multiple myeloma or B cell malignancies (33, 60). This evidence concerns the gene CCL19 and plasma cell myeloma.